Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178124 | 1.00 | KRAS (0.44) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21733472 | 0.95 | KRAS (0.43) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30178032 | 0.95 | KRAS (0.43) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21734067 | 0.94 | KRAS (0.39) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30177962 | 0.94 | KRAS (0.39) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21734026 | 0.91 | TLR9 (0.36) | KRASGPR119KDM4EALDH1A1HPGD | |
| SCHEMBL21733788 | 0.90 | KRAS (0.44) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21733528 | 0.90 | GPR119 (0.36) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL21733846 | 0.90 | KRAS (0.38) | KRASGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL30177751 | 0.90 | KRAS (0.38) | KRASGPR119SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KRAS 1/4885GPR119 1771/4885SMARCA2 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.